Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

African clinical trial denied access to key COVID drug Paxlovid

Supply shortages and limits on research leave low- and middle-income countries struggling to access Pfizer’s COVID-19 antiviral.
  1. Heidi Ledford
    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Amy Maxmen
    View author publications

    You can also search for this author in PubMed  Google Scholar

Researchers in a pivotal African clinical trial have been denied access to a key COVID-19 antiviral drug, frustrating efforts to test the treatment in African populations and in combination with therapies that could potentially expand its utility on the continent.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 604, 412-413 (2022)

doi: https://doi.org/10.1038/d41586-022-00919-5

References

  1. Hammon, J. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2118542 (2022).

    Article  PubMed  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links